Mirae Asset Global ETFs Holdings’s Candel Therapeutics CADL Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio CADL Stock Details CADL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$103K	Buy	21,073 +1,073	+5%	+$5.84K	﹤0.01%	2653
2025 Q4	$113K	Buy	20,000 +538	+3%	+$2.89K	﹤0.01%	2621
2025 Q3	$99.3K	Sell	19,462 -2,058	-10%	-$11.9K	﹤0.01%	2666
2025 Q2	$109K	Buy	21,520 +4,772	+28%	+$24.6K	﹤0.01%	2571
2025 Q1	$94.6K	Buy	16,748 +4,583	+38%	+$37.4K	﹤0.01%	2661
2024 Q4	$106K	Buy	12,165 +1,340	+12%	+$7.92K	﹤0.01%	2674
2024 Q3	$75K	Buy	+10,825	New	+$67.2K	﹤0.01%	2820

Other funds holding CADL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's CADL Position: Q1 2026 in Review

Mirae Asset Global ETFs Holdings increased its Candel Therapeutics (CADL) stake by 5.4% in Q1 2026, buying an estimated $5.84K and bringing the position to 21,073 shares worth $103K. The position accounts for ﹤0.01% of the portfolio, ranked #2653.

Mirae Asset Global ETFs Holdings first reported a position in CADL in Q3 2024 and has held it in 7 quarters since. The position peaked at $113K in Q4 2025. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

Mirae Asset Global ETFs Holdings held 21,073 shares of Candel Therapeutics worth $103K as of Q1 2026.
Mirae Asset Global ETFs Holdings bought 1,073 Candel Therapeutics shares in Q1 2026, an estimated $5.84K.
Candel Therapeutics made up ﹤0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q1 2026, its #2653 holding.
Mirae Asset Global ETFs Holdings first reported a position in Candel Therapeutics in Q3 2024 and has held it in 7 quarters since.
Mirae Asset Global ETFs Holdings's Candel Therapeutics position peaked at $113K in Q4 2025.
114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q1 2026, filed 15 May 2026.